Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. reports company developments tied to its transition into defense, security and rescue technology through Israeli subsidiaries including Zorronet and X Security & Defense. Zorronet develops AI-powered command-and-control software that connects cameras, sensors, drones and IoT devices into a unified environment for detection, classification, escalation and guided operational response.
Recurring BiomX news includes Zorronet product launches, customer deployments, critical-infrastructure applications, completed acquisitions, material agreements, advisory-board and governance updates, capital-structure disclosures and exchange-listing compliance matters. Company communications may also reference clinical and regulatory disclosures from BiomX’s legacy bacteriophage therapeutic programs.
BiomX (NYSE: PHGE) launched X Security & Defense LTD. in Israel on March 26, 2026 and will finance 2026 operations with over $3 million from internal funds. The company signed a non‑binding LOI for exclusive Israel distribution of an advanced aerial firefighting drone system.
BiomX aims to commercialize security, defense and first‑response technologies amid growing UAV emergency markets (UAV emergency responders: $3.2B 2023 → $9.6B 2032; firefighting drones: $1.8B 2023 → $4.5B 2032) and cites Israeli government emergency budgets exceeding $500 million.
BiomX (NYSE American: PHGE) CEO Michael Oster outlined a strategic and financial reset on March 19, 2026, aimed at stabilizing finances, simplifying capital structure, and unlocking future growth.
Key action: warrants from a December 2025 investment were amended to a one-year exercise period with an $1.00 exercise price, per the Form 8-K. Management is cutting non-essential costs, closing a Maryland facility, engaging banks and investors, and exploring repositioning toward defense-related opportunities.
BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.
BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.
BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.
BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.
BiomX (NYSE American: PHGE) announced a private placement expected to raise approximately $3.0 million in gross proceeds on December 29, 2025. The company said proceeds will support assessment of opportunities to advance BX011 and continued evaluation of strategic alternatives. H.C. Wainwright & Co. served as exclusive placement agent. Amounts are before placement agent fees and offering expenses.
BiomX (NYSE American: PHGE) announced on December 8, 2025 that it will discontinue the Phase 2b trial of nebulized phage therapy BX004 in cystic fibrosis after an internal review and recommendations from the independent Data Monitoring Committee following unusually high rates of adverse events.
The company said it will implement cost‑cutting measures, including a significant workforce reduction, and review strategic alternatives while refocusing development efforts on its bacteriophage program BX011 for Staphylococcus aureus diabetic foot infections, subject to available resources.
BiomX (NYSE American: PHGE) said the FDA is continuing to evaluate the nebulizer device used in its BX004 Phase 2b cystic fibrosis trial and the company is working with the device manufacturer to provide requested information to lift the clinical hold. An independent Data Monitoring Committee (DMC) completed a safety review after adverse events and recommended the study continue with adjusted dosing. BiomX will update the protocol and now expects topline results in Q2 2026, with U.S. enrollment to resume once device questions are resolved.
BiomX (NYSE:PHGE) will effect a 1-for-19 reverse stock split of its common stock, to trade on a split-adjusted basis when markets open on November 25, 2025. The company will file a Certificate of Amendment in Delaware and the new CUSIP after the split will be 09090D 509.
The split was approved by stockholders on October 16, 2025 and the Board fixed the final ratio on November 13, 2025. Outstanding shares are expected to be reduced from approximately 29,006,165 to approximately 1,526,640, with proportional adjustments to equity awards, warrants, convertible preferred stock and plan share pools. No fractional shares will be issued; holders entitled to fractions will be rounded up to the next whole share. Recordholders with certificates will receive instructions from Continental Stock Transfer & Trust Company; street-name holders need take no action.
BiomX (NYSE:PHGE) reported third quarter 2025 results and clinical updates on Nov 12, 2025. Key clinical points: positive FDA feedback on BX011 (S. aureus in diabetic foot infections) with a planned Phase 2a and FDA guidance outlining potential Phase 3 pathways for BX004 (P. aeruginosa in cystic fibrosis). The FDA has placed a U.S. clinical hold on the BX004 Phase 2b trial related to a third-party nebulizer; enrollment and dosing outside the U.S. continue and U.S. feedback is expected imminently. The company expects topline Phase 2b results in Q1 2026.
Financial highlights: cash and restricted cash $8.1M (Sept 30, 2025), sufficient to fund operations into Q1 2026; R&D $6.1M and G&A $2.4M in Q3; net loss $9.2M in Q3. Net cash used in operations was $22.0M for the nine months ended Sept 30, 2025.
BiomX (NYSE American: PHGE) will report third quarter 2025 financial results and program updates before U.S. market open on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:30 AM ET to discuss results and program progress.
Registration is recommended at least 5 minutes before the call; the webcast will be live and archived on the company website.